VF
SVA

Virtu Financial’s Sinovac Biotech, Ltd SVA Stock Holding History

Virtu Financial’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,119
Closed -$71K – 3483
2017
Q3 		$71K Buy
+10,119
New +$69.1K ﹤0.01% 2161

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Virtu Financial's SVA Position: Q4 2017 in Review

Virtu Financial sold out of Sinovac Biotech, Ltd (SVA) in Q4 2017, closing a stake of 10,119 shares — an estimated $71K sold.

Virtu Financial first reported a position in SVA in Q3 2017 and held it in 1 quarter. The position peaked at $71K in Q3 2017. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • Virtu Financial reported no remaining Sinovac Biotech, Ltd position as of Q4 2017 after selling out during the quarter.
  • Virtu Financial sold 10,119 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $71K.
  • Virtu Financial first reported a position in Sinovac Biotech, Ltd in Q3 2017 and held it in 1 quarter.
  • Virtu Financial's Sinovac Biotech, Ltd position peaked at $71K in Q3 2017.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on Virtu Financial's 13F filing for Q4 2017, filed 9 Feb 2018.